MedTrace Logo

Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients

NCT01214174 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2013-09-18

Study results available
· View outcomes & findings →

Summary

This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after cataract surgery.

Conditions

  • Ocular Inflammation

Interventions

DRUG

IBI-10090

Sponsors & Collaborators

  • ICON Bioscience Inc

    lead INDUSTRY

Principal Investigators

  • Mark Packer, MD · Drs. Fine, Hoffman, Packer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01214174 on ClinicalTrials.gov